MX9601031A - Composicion farmaceutica para el tratamiento y prevencion del cancer de prostata. - Google Patents

Composicion farmaceutica para el tratamiento y prevencion del cancer de prostata.

Info

Publication number
MX9601031A
MX9601031A MX9601031A MX9601031A MX9601031A MX 9601031 A MX9601031 A MX 9601031A MX 9601031 A MX9601031 A MX 9601031A MX 9601031 A MX9601031 A MX 9601031A MX 9601031 A MX9601031 A MX 9601031A
Authority
MX
Mexico
Prior art keywords
prostatic cancer
prevention
treatment
preventing
prostatic
Prior art date
Application number
MX9601031A
Other languages
English (en)
Inventor
James Edmund Audia
Blake Lee Neubauer
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/408,745 external-priority patent/US5629007A/en
Priority claimed from US08/407,822 external-priority patent/US5635197A/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX9601031A publication Critical patent/MX9601031A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

La presente invencion proporciona el uso para la fabricacion de un medicamento para: evitar el desarrollo del cáncer prostático en un paciente que tiene riesgo de tal cáncer o evitar o tratar la metástasis a los huesos del cáncer prostático; de un compuesto de la formula: (Ver Formula), en donde los significados de los radicales R, R1, R2, R3, R4 y X-R5 y (R6)m se describen en detalle en la descripcion.
MX9601031A 1995-03-21 1996-03-19 Composicion farmaceutica para el tratamiento y prevencion del cancer de prostata. MX9601031A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/408,745 US5629007A (en) 1995-03-21 1995-03-21 Method of preventing prostatic cancer development
US08/407,822 US5635197A (en) 1995-03-21 1995-03-21 Treatment and prevention of prostatic cancer metastasis

Publications (1)

Publication Number Publication Date
MX9601031A true MX9601031A (es) 1997-02-28

Family

ID=27020024

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9601031A MX9601031A (es) 1995-03-21 1996-03-19 Composicion farmaceutica para el tratamiento y prevencion del cancer de prostata.

Country Status (14)

Country Link
EP (1) EP0733365A3 (es)
JP (1) JPH08277220A (es)
KR (1) KR960034202A (es)
AU (1) AU695860B2 (es)
CA (1) CA2172211A1 (es)
CZ (1) CZ287977B6 (es)
HU (1) HUP9600702A3 (es)
IL (1) IL117537A (es)
MX (1) MX9601031A (es)
NO (1) NO961113L (es)
SG (1) SG47093A1 (es)
TW (1) TW450809B (es)
YU (1) YU16196A (es)
ZA (1) ZA962141B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5550134A (en) * 1995-05-10 1996-08-27 Eli Lilly And Company Methods for inhibiting bone loss
US6111110A (en) * 1996-10-30 2000-08-29 Eli Lilly And Company Synthesis of benzo[f]quinolinones
CA2270433A1 (en) * 1996-10-30 1998-05-07 Eli Lilly And Company Synthesis of benzo¬f|quinolinones
AU754604B2 (en) * 1998-07-29 2002-11-21 Merck & Co., Inc. Tricyclic compounds
US6436489B1 (en) 1999-03-24 2002-08-20 Clariant International Ltd. Fluorine-containing benzothiazoles, and their use in liquid-crystalline mixtures
GB0419850D0 (en) * 2004-09-07 2004-10-13 Angeletti P Ist Richerche Bio Therapeutic agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0591583B1 (en) * 1991-08-21 2001-12-19 Eli Lilly And Company Benzo (f) quinolinones as 5-alpha-reductase inhibitors
US5239075A (en) * 1991-08-21 1993-08-24 Eli Lilly And Company Process for the preparation of benzo (f) quinolinones

Also Published As

Publication number Publication date
SG47093A1 (en) 1998-03-20
JPH08277220A (ja) 1996-10-22
CZ287977B6 (cs) 2001-03-14
HU9600702D0 (en) 1996-05-28
YU16196A (sh) 1998-11-05
IL117537A (en) 2001-01-11
EP0733365A2 (en) 1996-09-25
EP0733365A3 (en) 1997-03-05
HUP9600702A2 (en) 1996-12-30
AU4816896A (en) 1996-10-03
NO961113D0 (no) 1996-03-19
HUP9600702A3 (en) 1997-04-28
AU695860B2 (en) 1998-08-27
CZ82596A3 (en) 1996-10-16
KR960034202A (ko) 1996-10-22
IL117537A0 (en) 1996-07-23
TW450809B (en) 2001-08-21
CA2172211A1 (en) 1996-09-22
NO961113L (no) 1996-09-23
ZA962141B (en) 1997-09-15

Similar Documents

Publication Publication Date Title
AP1401A (en) Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of manic- depressive bipolar disorder.
UA32429C2 (uk) Засіб для лікування нетримання сечі
DE59611481D1 (en) Chromatin-regulatorgene
ZA972929B (en) Systems for the treatment of commingled wastes and methods for treating commingled wastes.
ZA9610249B (en) Treatment of vegetables.
PL323825A1 (en) Peptidyloheterocycli compounds useful in treating diorders associated with thrombosin
HU9602965D0 (en) Cancer treatment and metastasis prevention
NZ297320A (en) 2-(2-amino-3-methoxyphenyl)-4-oxo-4h-[1]-benzopyran and medicaments
MX9700534A (es) Uso de droloxifeno y sus sales farmaceuticamente aceptables en la preparacion de remedios para tratar las enfermedades de prostata, endometriosis y obesidad.
CA2301032A1 (en) A method of preventing or treating estrogen-dependent diseases and disorders
HUP9801413A3 (en) Waste water treatment, media therefor and its manufacture
PL324750A1 (en) Expressive construct p16 and posiibility of using it in treating carcinomas
UA66793C2 (uk) Лептин як стримувач швидкого збільшення пухлини клітини
MX9702035A (es) Inhibidores de 5-alfa reductasa.
PL313349A1 (en) Method of diagnoasing, progdnosticating and treating non-lymphatic tumours and their metastases
MX9601031A (es) Composicion farmaceutica para el tratamiento y prevencion del cancer de prostata.
PL322903A1 (en) Sewage treatment plant
MD798G2 (ro) Metoda de tratament a cancerului mamar
DE69526731D1 (en) Hypocholesterolämische,antiatherosklerotische und hypotriglyceridämische mercaptoacetylamid-derivate
EP0839032A4 (en) HYDROXYL IONS AS SPECIAL THERAPEUTIC AGENTS, AND COMPOUNDS SUITABLE TO MODULATE THESE IONS, COMPOUNDS
ES2190581T3 (es) 2-aminotetralina opticamente activa, procedimiento para su preparacion y composiciones farmaceuticas que la contienen, activa en la prevencion y tratamiento de shock septico.
MX9708190A (es) Metodo para tratar dioxido de cloro.
UA22099A (uk) Спосіб хірургічhого лікуваhhя місцево-розповсюджеhого раку ободової кишки
ZA964382B (en) Lymphotoxin and thrombopoietin for use in the treatment of cancer.
GR3032072T3 (en) Transdermal therapeutical system for silatran compounds

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees